After decades of failure in the quest for an RSV vaccine, doctors are anxious to finally have something to offer especially after a virus surge that strained hospitals last fall.
The FDA decision Wednesday makes GSK's shot the first of several RSV vaccines in the pipeline to be licensed. The move sets the stage for adults 60 and older to get vaccinated this fall.